Insulet (NASDAQ:PODD) Stock Moved Up to Hold by Barclays

Barclays upgraded shares of Insulet (NASDAQ:PODD) to a hold rating in a research note published on Wednesday morning,Zacks reports.

PODD has been the subject of a number of other research reports. Sanford C. Bernstein dropped their target price on Insulet from $200.00 to $175.00 and set an “outperform” rating for the company in a report on Thursday, August 6th. Truist Financial restated a “hold” rating and issued a $153.00 price target (down from $210.00) on shares of Insulet in a research note on Wednesday, August 5th. Oppenheimer lowered shares of Insulet from an “outperform” rating to a “market perform” rating in a research report on Wednesday, August 5th. Leerink Partners cut shares of Insulet from an “outperform” rating to a “market perform” rating and dropped their price objective for the stock from $247.00 to $145.00 in a research note on Thursday, August 6th. Finally, JPMorgan Chase & Co. reissued a “neutral” rating and issued a $152.00 price objective (down from $275.00) on shares of Insulet in a report on Thursday, August 6th. Thirteen analysts have rated the stock with a Buy rating, twelve have issued a Hold rating and one has issued a Sell rating to the company’s stock. Based on data from MarketBeat, the company has an average rating of “Hold” and a consensus price target of $193.48.

Insulet Price Performance

Insulet stock opened at $134.36 on Wednesday. The company has a market capitalization of $9.32 billion, a price-to-earnings ratio of 25.11, a PEG ratio of 1.06 and a beta of 1.11. The company has a current ratio of 2.48, a quick ratio of 1.83 and a debt-to-equity ratio of 0.65. Insulet has a 12 month low of $126.40 and a 12 month high of $354.88. The stock’s 50 day moving average is $142.95 and its 200-day moving average is $160.47.

Insulet (NASDAQ:PODD) last released its quarterly earnings results on Wednesday, August 5th. The medical instruments supplier reported $1.66 earnings per share for the quarter, topping the consensus estimate of $1.47 by $0.19. The business had revenue of $801.70 million during the quarter, compared to analysts’ expectations of $787.39 million. Insulet had a return on equity of 29.29% and a net margin of 12.29%.The firm’s revenue for the quarter was up 23.5% compared to the same quarter last year. During the same period last year, the firm posted $1.17 EPS. Insulet has set its FY 2026 guidance at 6.460- EPS. Equities research analysts expect that Insulet will post 6.51 EPS for the current year.

Institutional Inflows and Outflows

A number of hedge funds have recently modified their holdings of PODD. Elevation Wealth Partners LLC raised its position in shares of Insulet by 115.6% in the 3rd quarter. Elevation Wealth Partners LLC now owns 194 shares of the medical instruments supplier’s stock valued at $25,000 after buying an additional 104 shares in the last quarter. Moody National Bank Trust Division boosted its position in shares of Insulet by 150.9% during the 3rd quarter. Moody National Bank Trust Division now owns 5,442 shares of the medical instruments supplier’s stock worth $710,000 after acquiring an additional 3,273 shares in the last quarter. QRG Capital Management Inc. increased its stake in Insulet by 142.4% in the second quarter. QRG Capital Management Inc. now owns 3,851 shares of the medical instruments supplier’s stock valued at $586,000 after acquiring an additional 2,262 shares during the last quarter. Talon Private Wealth LLC raised its position in Insulet by 92.0% during the second quarter. Talon Private Wealth LLC now owns 5,124 shares of the medical instruments supplier’s stock valued at $780,000 after purchasing an additional 2,455 shares in the last quarter. Finally, Sequoia Financial Advisors LLC lifted its stake in Insulet by 26.0% during the second quarter. Sequoia Financial Advisors LLC now owns 4,042 shares of the medical instruments supplier’s stock worth $615,000 after purchasing an additional 834 shares during the last quarter.

About Insulet

Insulet Corporation is a medical device company that develops, manufactures and markets wearable insulin delivery systems for people with diabetes. The company is best known for its Omnipod platform, which is designed to provide insulin delivery without the tubing traditionally associated with conventional insulin pumps.

Insulet’s product portfolio includes the Omnipod 5 Automated Insulin Delivery System, a tubeless, wearable system that integrates with continuous glucose monitoring technology to automate insulin delivery, as well as the Omnipod DASH system.